- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01373944
Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI
December 20, 2013 updated by: Aspire Foundation
Rapid-Acquisition Low-Dosimetry Tc-99m Stress-Only Myocardial Perfusion SPECT on the Spectrum Dynamics System: Comparison of Efficiency and Outcomes With Stress-Only Anger SPECT
The purpose of this study is to compare clinical efficiency and patient outcomes using ultra low-dose stress only Tc-99m and solid-state SPECT versus traditional Anger SPECT.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Saint Luke's Cardiovascular Imaging Center
-
Kansas City, Missouri, United States, 64154
- Saint Luke's North Cardiovascular Imaging Center
-
Lee's Summit, Missouri, United States, 64086
- Saint Luke's East Cardiovascular Imaging Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Consecutive patients referred for clinically-indicated myocardial perfusion SPECT
Description
Inclusion Criteria:
- BMI < 35 kg/m2
- LVEF > 40%
- Exercise stress
- Elective out-patients
- No known CAD (>50%) by catheterization
- No history of prior myocardial infarction
Exclusion Criteria:
- LBBB
- Pacemaker
- Atrial Fibrillation
- Frequent PAC's or PVC's
- Inability to achieve at least 6 minutes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Stress Only SPECT MPI with Anger Camera
Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
|
|
Stress Only SPECT MPI with SD Camera
Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Failure
Time Frame: 30 days
|
Diagnostic failure is defined by a composite of need for additional downstream testing (anger SPECT, MPI PET, stress echocardiography or coronary CT angiography) within 30 days or a coronary angiogram with no stenoses greater than or equal to 50% severity using quantitative coronary angiography.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Necessity to proceed to a rest image
Time Frame: 30 days
|
The first of 4 secondary end-points is the need to proceed to a rest image.
|
30 days
|
|
Necessity for additional downstream testing
Time Frame: 30 days
|
The second of four secondary endpoints the need for additional downstream testing within 30 days to address the same clincial reason for the innitial referral for stress-onoly imaging, in the absence of any changes in clincial status between tests.
|
30 days
|
|
Coronary Angiography
Time Frame: 60 to 90 days
|
The third of four secondary end-points is the occurrence of coronary angiography with no stenoses greater than or equal to 50% severity using quantitative coronary angiography.
|
60 to 90 days
|
|
Determine optimal performance of the Spectrum Dynamics camera system for stress only imaging
Time Frame: 60 to 90 days
|
The fourth of four secondary endpoints is to determine optimal performance of the Spectrum Dynamics camera system for stress only imaging: upright imaging alone, supine imaging alone, or both in terms of primary and secondary endpoints
|
60 to 90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy M Bateman, MD, Aspire Foundation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
June 14, 2011
First Submitted That Met QC Criteria
June 14, 2011
First Posted (Estimate)
June 15, 2011
Study Record Updates
Last Update Posted (Estimate)
December 23, 2013
Last Update Submitted That Met QC Criteria
December 20, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D-Spect Stress Only
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.